Literature DB >> 19223863

Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.

Nelson C Di Paolo1, Nico van Rooijen, Dmitry M Shayakhmetov.   

Abstract

Human adenovirus (Ad) is a ubiquitous pathogen causing a wide range of diseases. Although the interactions of human Ad serotype 5 (Ad5) with susceptible cells in vitro are known in great detail, host factors controlling the tissue specificity of Ad5 infection in vivo remain poorly understood. Here, we analyzed the mechanisms of sequestration by the liver for blood-born human Ads and Ad5-based vectors. Our data suggest that several known mechanisms that lead to Ad5 sequestration by the liver become engaged in a redundant, sequential, and synergistic manner to ensure the rapid clearance of circulating virus particles from the blood. These mechanisms include (i) trapping of the virus by liver residential macrophages, Kupffer cells; (ii) Ad5 hepatocyte infection via blood factor-hexon interactions; and (iii) Ad5 penton RGD motif-mediated interactions with liver endothelial cells and hepatocytes, mediating virus retention in the space of Disse. More important, we show that when all of these mechanisms are simultaneously inactivated via mutations of Ad5 capsid proteins and pharmacological interventions, virus sequestration by the liver is markedly reduced. Therefore, our study is the first demonstration of the principal possibility of ablating the sequestration of blood-born Ad in the liver via specific inactivation of a defined set of mechanisms that control this process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223863      PMCID: PMC2835106          DOI: 10.1038/mt.2008.307

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Dependence of adenovirus infectivity on length of the fiber shaft domain.

Authors:  D M Shayakhmetov; A Lieber
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Adenovirus type 11 uses CD46 as a cellular receptor.

Authors:  Anna Segerman; John P Atkinson; Marko Marttila; Veronica Dennerquist; Göran Wadell; Niklas Arnberg
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.

Authors:  Jan Snoeys; Geertrui Mertens; Joke Lievens; Theo van Berkel; Désiré Collen; Erik A L Biessen; Bart De Geest
Journal:  Mol Ther       Date:  2005-08-19       Impact factor: 11.454

5.  Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses.

Authors:  Todd Machemer; Heidrun Engler; Van Tsai; Seoju Lee; Susan Cannon-Carlson; Marcio Voloch; Thomas Schluep; Sundari Ravindran; Gary Vellekamp; Elena Brin; Douglas Cornell; Suganto Sutjipto; Shu Fen Wen; Mark Horn; Nico Van Rooijen; Dan Maneval; Beth Hutchins; Drake LaFace
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

6.  Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver.

Authors:  N Tao; G P Gao; M Parr; J Johnston; T Baradet; J M Wilson; J Barsoum; S E Fawell
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

7.  Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers.

Authors:  H Fechner; A Haack; H Wang; X Wang; K Eizema; M Pauschinger; R Schoemaker; R Veghel; A Houtsmuller; H P Schultheiss; J Lamers; W Poller
Journal:  Gene Ther       Date:  1999-09       Impact factor: 5.250

8.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.

Authors:  P W Roelvink; G Mi Lee; D A Einfeld; I Kovesdi; T J Wickham
Journal:  Science       Date:  1999-11-19       Impact factor: 47.728

9.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

10.  Blood clearance rates of adenovirus type 5 in mice.

Authors:  Ramon Alemany; Kaori Suzuki; David T Curiel
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

View more
  36 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

2.  FX and host defense evasion tactics by adenovirus.

Authors:  Andrew H Baker; Stuart A Nicklin; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

Review 3.  Helper-dependent adenoviral vectors for liver-directed gene therapy.

Authors:  Nicola Brunetti-Pierri; Philip Ng
Journal:  Hum Mol Genet       Date:  2011-04-05       Impact factor: 6.150

4.  Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.

Authors:  Ping Wu; Tarana A Kudrolli; Wasim H Chowdhury; Minzhi M Liu; Ronald Rodriguez; Shawn E Lupold
Journal:  Cancer Res       Date:  2010-07-29       Impact factor: 12.701

5.  Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Authors:  Robert A Adair; Victoria Roulstone; Karen J Scott; Ruth Morgan; Gerard J Nuovo; Martin Fuller; Deborah Beirne; Emma J West; Victoria A Jennings; Ailsa Rose; Joan Kyula; Sheila Fraser; Rajiv Dave; David A Anthoney; Alison Merrick; Robin Prestwich; Amer Aldouri; Oliver Donnelly; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Giles Toogood; Kevin Harrington; Alan A Melcher
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

6.  Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.

Authors:  Joshua J Short; Angel A Rivera; Hongju Wu; Mark R Walter; Masato Yamamoto; J Michael Mathis; David T Curiel
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

7.  Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Authors:  Reeti Khare; Matthew L Hillestad; Zhili Xu; Andrew P Byrnes; Michael A Barry
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Authors:  Angela C Bradshaw; Alan L Parker; Margaret R Duffy; Lynda Coughlan; Nico van Rooijen; Veli-Matti Kähäri; Stuart A Nicklin; Andrew H Baker
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

Review 9.  The role of liver sinusoidal cells in hepatocyte-directed gene transfer.

Authors:  Frank Jacobs; Eddie Wisse; Bart De Geest
Journal:  Am J Pathol       Date:  2009-11-30       Impact factor: 4.307

Review 10.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.